Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–15. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. [2011 Sep 23];11(10):719–725. doi: 10.1038/nrc3144
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284–296. doi: 10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul;69(4):280–304. doi: 10.3322/caac.21559
   PubMed Web of Science ®Google Scholar
• Pokhriyal R, Hariprasad R, Kumar L, et al. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1179299X19860815. doi: 10.1177/1179299X19860815
   PubMedGoogle Scholar
• Aguilera A, Gómez-González B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008 Mar;9(3):204–217. doi: 10.1038/nrg2268
   PubMed Web of Science ®Google Scholar
• Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998 Oct;24(5):331–344. doi: 10.1016/s0305-7372(98)90056-1
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016 Feb;16(2):110–120. doi: 10.1038/nrc.2015.21
   PubMed Web of Science ®Google Scholar
• Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. [2011 Jun 29];474(7353):609–615. doi: 10.1038/nature10166
   PubMed Web of Science ®Google Scholar
• Oza AM, Matulonis UA, Alvarez Secord A, et al. A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. Clin Cancer Res. [2020 Mar 1];26(5):1009–1016. doi: 10.1158/1078-0432.CCR-19-1638
   PubMed Web of Science ®Google Scholar
• Cardenas H, Fang F, Jiang G, et al. Methylomic signatures of high grade serous ovarian cancer. Epigenetics. 2021 Nov;16(11):1201–1216. doi: 10.1080/15592294.2020.1853402
   PubMed Web of Science ®Google Scholar
• Cao YL, Zhuang T, Xing BH, et al. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer. Cell Biochem Funct. 2017 Aug;35(6):296–303. doi: 10.1002/cbf.3276
   PubMed Web of Science ®Google Scholar
• Balch C, Fang F, Matei DE, et al. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 2009 Sep;150(9):4003–4011. doi: 10.1210/en.2009-0404
   PubMed Web of Science ®Google Scholar
• Fiegl H, Windbichler G, Mueller-Holzner E, et al. HOXA11 DNA methylation–a novel prognostic biomarker in ovarian cancer. Int J Cancer. [2008 Aug 1];123(3):725–729. doi: 10.1002/ijc.23563
   PubMed Web of Science ®Google Scholar
• Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. [2011 Aug 7];43(9):879–882. doi: 10.1038/ng.893
   PubMed Web of Science ®Google Scholar
• Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010 May;42(5):410–414. doi: 10.1038/ng.569
   PubMed Web of Science ®Google Scholar
• Luo S, Wang Y, Tao Y, et al. Application in gene editing in ovarian cancer therapy. Cancer Invest. 2022 Apr;40(4):387–399. doi: 10.1080/07357907.2021.1998521
   PubMed Web of Science ®Google Scholar
• Norouzi-Barough L, Sarookhani M, Salehi R, et al. CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line. Iran J Basic Med Sci. 2018 Feb;21(2):181–187. doi: 10.22038/IJBMS.2017.25145.6230
   PubMed Web of Science ®Google Scholar
• Walton JB, Farquharson M, Mason S, et al. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci Rep. [2017 Dec 4];7(1):16827. doi: 10.1038/s41598-017-17119-1
   PubMedGoogle Scholar
• Kim SM, Yang Y, Oh SJ, et al. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. [2017 Nov 28];266:8–16. doi: 10.1016/j.jconrel.2017.09.013
   PubMed Web of Science ®Google Scholar
• Sonego M, Pellarin I, Costa A, et al. USP1 links platinum resistance to cancer cell dissemination by regulating snail stability. Sci Adv. 2019 May;5(5):eaav3235. doi: 10.1126/sciadv.aav3235
   PubMed Web of Science ®Google Scholar
• Li L, He ZY, Wei XW, et al. Challenges in CRISPR/CAS9 delivery: Potential roles of nonviral vectors. Hum Gene Ther. 2015 Jul;26(7):452–462. doi: 10.1089/hum.2015.069
   PubMed Web of Science ®Google Scholar
• Nuñez JK, Chen J, Pommier GC, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. [2021 Apr 29];184(9):2503–2519. e17 doi:10.1016/j.cell.2021.03.025
   PubMed Web of Science ®Google Scholar
• Horlbeck MA, Gilbert LA, Villalta JE, et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife. [2016 Sep 23]:5. doi: 10.7554/eLife.19760
   Web of Science ®Google Scholar
• Marquard AM, Eklund AC, Joshi T, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3(1):9. doi: 10.1186/s40364-015-0033-4
   PubMedGoogle Scholar
• Kalachand RD, Stordal B, Madden S, et al. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: An individual patient data meta-analysis. J Natl Cancer Inst. [2020 Dec 14];112(12):1190–1203. doi: 10.1093/jnci/djaa070
   PubMedGoogle Scholar
• Kondrashova O, Topp M, Nesic K, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun. [2018 Sep 28];9(1):3970. doi: 10.1038/s41467-018-05564-z
   PubMedGoogle Scholar
• Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016 Jun;60:49–58. doi: 10.1016/j.ejca.2016.03.005
   PubMed Web of Science ®Google Scholar
• Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016 Aug;27(8):1449–1455. doi: 10.1093/annonc/mdw142
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. [2005 Apr 14];434(7035):917–921. doi: 10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. [2009 Jul 9];361(2):123–134. doi: 10.1056/NEJMoa0900212
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421–440. doi: 10.1038/nrd1718
   PubMed Web of Science ®Google Scholar
• Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. [2007 Mar 1];13(5):1383–1388. doi: 10.1158/1078-0432.CCR-06-2260
   PubMed Web of Science ®Google Scholar
• Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta. 2014 Aug;1846(1):201–215. doi: 10.1016/j.bbcan.2014.07.004
   PubMed Web of Science ®Google Scholar
• Wang M, Wu W, Rosidi B, et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006;34(21):6170–6182. doi: 10.1093/nar/gkl840
   PubMed Web of Science ®Google Scholar
• Catteau A, Harris WH, Xu CF, et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. [1999 Mar 18];18(11):1957–1965. doi: 10.1038/sj.onc.1202509
   PubMed Web of Science ®Google Scholar
• Pradjatmo H, Dasuki D, Anwar M, et al. Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(21):9479–9485. doi: 10.7314/apjcp.2014.15.21.9479
   PubMedGoogle Scholar
• Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. [2012 Nov 6];107(10):1776–1782. doi: 10.1038/bjc.2012.451
   PubMed Web of Science ®Google Scholar
• Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. [2000 Oct 1];60(19):5329–5333.
   PubMed Web of Science ®Google Scholar
• Geisler JP. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst. [2002 Jan 2];94(1):61–67. doi: 10.1093/jnci/94.1.61
   PubMedGoogle Scholar
• Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. [2007 Dec 15];13(24):7421–7431. doi: 10.1158/1078-0432.CCR-07-0760
   PubMed Web of Science ®Google Scholar
• Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. [2012 Jan 25];307(4):382–390. doi: 10.1001/jama.2012.20
   PubMed Web of Science ®Google Scholar
• Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. [2011 Oct 12];306(14):1557–1565. doi: 10.1001/jama.2011.1456
   PubMed Web of Science ®Google Scholar
• Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. [2008 Jan 22];8:17. doi: 10.1186/1471-2407-8-17
   PubMed Web of Science ®Google Scholar
• Swisher EM, Gonzalez RM, Taniguchi T, et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. [2009 Jul 14];8:48. doi: 10.1186/1476-4598-8-48
   PubMed Web of Science ®Google Scholar
• Wang C, Horiuchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 2004 Feb;202(2):215–223. doi: 10.1002/path.1507
   PubMed Web of Science ®Google Scholar
• Stordal B, Timms K, Farrelly A, et al. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013 Jun;7(3):567–579. doi: 10.1016/j.molonc.2012.12.007
   PubMed Web of Science ®Google Scholar
• Veeck J, Ropero S, Setien F, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. [2010 Oct 10];28(29):e563–4; author reply e565-6. doi:10.1200/JCO.2010.30.1010
   PubMed Web of Science ®Google Scholar
• Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014 May;8(3):656–668. doi: 10.1016/j.molonc.2014.01.008
   PubMed Web of Science ®Google Scholar
• Menghi F, Banda K, Kumar P, et al. Genomic and epigenomic. Sci Transl Med. [2022 Jul 6];14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926
   PubMedGoogle Scholar
• Fernandez SV, Huang Y, Snider KE, et al. Expression and DNA methylation changes in human breast epithelial cells after bisphenol a exposure. Int J Oncol. 2012 Jul;41(1):369–377. doi: 10.3892/ijo.2012.1444
   PubMed Web of Science ®Google Scholar
• Al-Yousef N, Shinwari Z, Al-Shahrani B, et al. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncol Rep. 2020 Mar;43(3):827–838. doi: 10.3892/or.2020.7473
   PubMed Web of Science ®Google Scholar